/
INSM
$106.70+$1.96 (+1.87%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$22.4B
217M shares
52-week range
$90.39 – $212.75
13% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.34%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$77.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $136.5M | $164.4M | $188.5M | $245.4M | $305.2M | $363.7M | $606.4M |
| Cost of revenue | $2.4M | $24.2M | $39.9M | $44.2M | $55.1M | $65.6M | $85.7M | $124.9M |
| Gross profit | $7.4M | $112.3M | $124.5M | $144.3M | $190.2M | $239.6M | $278.0M | $481.5M |
| Gross margin | 75.4% | 82.3% | 75.7% | 76.6% | 77.5% | 78.5% | 76.4% | 79.4% |
| R&D | $145.3M | $131.7M | $181.2M | $272.7M | $397.5M | $571.0M | $598.4M | $771.1M |
| Operating income | −$307.3M | −$235.2M | −$265.2M | −$375.1M | −$457.3M | −$709.6M | −$878.3M | −$1.18B |
| EBITDA | −$295.2M | −$217.1M | −$250.4M | −$383.6M | −$447.4M | −$660.2M | −$818.8M | −$1.17B |
| Net income | −$324.3M | −$254.3M | −$294.1M | −$434.7M | −$481.5M | −$749.6M | −$913.8M | −$1.28B |
| Net margin | -3297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| EPS (diluted) | -4.22 | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.7B | $-2.70 | $-4.39–$-1.95 | 15 |
| 2027 | $2.7B | $0.35 | $-0.25–$0.97 | 15 |
| 2028 | $3.7B | $3.34 | $0.55–$6.59 | 17 |
| 2029 | $4.9B | $7.01 | $5.78–$7.84 | 13 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
www.insmed.com- Employees
- 1,664
- IPO / List date
- Jun 1, 2000
- HQ
- BRIDGEWATER, NJ
Held by traders on TradeandTell
No one on the platform currently holds INSM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 295,579 | $48.3M |
| Renaissance Technologiesas of 2026-03-31 | 20,300 | $3.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2011-03-03 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded INSM yet.
